- Report
- March 2024
- 197 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- March 2024
- 185 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- May 2024
- 299 Pages
Global
From €5237EUR$5,450USD£4,477GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,126USD£894GBP
- Report
- January 2024
- 150 Pages
Global
From €4660EUR$4,850USD£3,984GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- March 2024
- 184 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4756EUR$4,950USD£4,066GBP
- Report
- March 2022
- 300 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- May 2020
- 185 Pages
Global
From €3987EUR$4,150USD£3,409GBP
- Report
- January 2023
- 125 Pages
Global
From €2392EUR$2,490USD£2,045GBP
- Report
- April 2023
- 115 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2022
- 419 Pages
Global
From €9128EUR$9,500USD£7,804GBP
- Report
- April 2023
- 117 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- July 2022
- 100 Pages
Global
From €2642EUR$2,750USD£2,259GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more